Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

G Protein-coupled Receptors01:15

G Protein-coupled Receptors

19.5K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
19.5K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

2.4K
2.4K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

88.8K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
88.8K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

6.3K
6.3K
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

7.4K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
7.4K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

20.6K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Confining thrombus morphospace through targeted inhibition of platelet mechanosensory signaling.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Growth factor independent 1B is a metabolic regulator that exerts pleiotropic effects on platelet function.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Finding and following: a deep learning-based pipeline for tracking platelets during thrombus formation <i>in vivo</i> and <i>ex vivo</i>.

Platelets·2024
Same author

Megakaryocytes possess a STING pathway that is transferred to platelets to potentiate activation.

Life science alliance·2023
Same author

PI3KC2α inhibition is antithrombotic in blood from hypercholesterolemic mice.

Journal of thrombosis and haemostasis : JTH·2023
Same author

A microfluidic method to investigate platelet mechanotransduction under extensional strain.

Research and practice in thrombosis and haemostasis·2023
Same journal

Glucagon-like peptide-1 improves vascular endothelial dysfunction in hypertensive mice via CREB-driven transcriptional regulation of long non-coding RNA 155383.

British journal of pharmacology·2026
Same journal

The chemokine receptor-like fourth extracellular loop of the apelin receptor differentially regulates apelin and elabela binding and signalling.

British journal of pharmacology·2026
Same journal

Peripheral targets for neuropathic pain.

British journal of pharmacology·2026
Same journal

Therapeutic potential of liver X receptor agonist GW3965 in preserving myelin integrity following traumatic brain injury.

British journal of pharmacology·2026
Same journal

The role of protein arginine methyltransferases in sickle cell-mediated neurovascular impairments in mice.

British journal of pharmacology·2026
Same journal

β-Cyclodextrin inclusion enhances the pro-resolving effects of the annexin A1 mimetic Ac2-26 in a mouse model of antigen-induced arthritis.

British journal of pharmacology·2026
See all related articles

Related Experiment Video

Updated: Mar 26, 2026

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.0K

Protease-activated receptor 4: from structure to function and back again.

Shauna L French1, Justin R Hamilton2

  • 1Australian Centre for Blood Diseases, Monash University, Melbourne, Australia.

British Journal of Pharmacology
|February 5, 2016
PubMed
Summary
This summary is machine-generated.

Protease-activated receptors (PARs) are GPCRs with therapeutic potential. This review focuses on PAR4, detailing its discovery, function, and potential in disease treatment.

More Related Videos

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

4.0K
Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4
12:09

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4

Published on: December 31, 2013

10.7K

Related Experiment Videos

Last Updated: Mar 26, 2026

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.0K
A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

4.0K
Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4
12:09

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4

Published on: December 31, 2013

10.7K

Area of Science:

  • Molecular Pharmacology
  • G Protein-Coupled Receptors

Background:

  • Protease-activated receptors (PARs) are a family of four G protein-coupled receptors (GPCRs) with unique properties.
  • While PAR1 and PAR2 have been extensively studied, PAR3 and PAR4 remain less understood.
  • The recent approval of a PAR1 antagonist highlights the clinical relevance of targeting these receptors.

Purpose of the Study:

  • To review the discovery, structure, pharmacology, and physiological significance of PAR4.
  • To explore the emerging evidence for PAR4's role in disease.
  • To discuss the therapeutic potential of targeting PAR4.

Main Methods:

  • Literature review of published studies on PAR4.
  • Analysis of pharmacological and genetic tools for PAR4 research.
  • Synthesis of current knowledge on PAR4 physiology and disease association.

Main Results:

  • PAR4, like other PARs, is implicated in various physiological processes.
  • Emerging evidence suggests PAR4 plays a role in specific disease settings.
  • Pharmacological and genetic tools are becoming available for detailed PAR4 investigation.

Conclusions:

  • PAR4 represents a promising therapeutic target due to its involvement in disease.
  • Further research into PAR4's function is crucial for developing new treatments.
  • Targeting PAR4 holds significant clinical potential for various conditions.